ArticleEuropean radiology2026
How best to combine DWI and T2WI to predict pathologic complete response: a multi-center study on interpreting MRI following chemoradiotherapy of rectal cancer.
Article in European radiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Magnetic Resonance Imaging After Total Neoadjuvant Therapy in Rectal Cancer: Treatment-Oriented Response Assessment and Reporting for Watch-and-Wait Management.Korean journal of radiology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
objectivesTo explore the different criteria of integrating diffusion-weighted imaging (DWI) for predicting pathologic complete response (pCR) of rectal cancer on post-chemoradiotherapy (CRT) MRI. MATERIALS AND
methodsIn this multi-center retrospective study, five radiologists reviewed pre- and post-CRT MRIs of patients with rectal cancer diagnosed in 2017-2021. In addition to mrTRG, three criteria were assessed: "AND" criterion (mrTRG 1-2 and absence of DWI restriction considered as CR), "OR" criterion (mrTRG 1-2 or absence of restriction), and a modified MR tumor regression grade (modMR-TRG). A crossed random effects model was used to pool sensitivity and specificity across five radiologists. F1 score and positive predictive value (PPV) were analyzed across varying pCR rates.
resultsIn 146 patients (median age [IQR], 63 [57-70] years; 87 men), the AND criterion yielded higher specificity (77.4% [63.3-80.0%] vs 75.3% [60.5-79.0%], p = 0.001) without significant difference in sensitivity (63.9% [42.8-75.3%] vs 67.5% [45.3-76.0%], p = 0.063) compared with mrTRG. OR criterion yielded higher sensitivity (86.1% [65.3-89.3%]; p < 0.001) but lower specificity (49.5% [36.2-62.6%]; p < 0.001). The modMR-TRG demonstrated similar effects to the OR criterion. Assuming a 20% pCR rate, PPV and F1 score of the AND criterion (point estimate of 41.4% and 50.3%, respectively) were higher than those of the OR criterion (PPV, 29.9%; F1 score, 44.4%), although the difference diminished with increasing pCR rate.
conclusionThe AND criterion-which utilizes DWI complementarily to further exclude patients with residual tumors after initial screening on T2WI-should be preferred over other criteria giving greater emphasis on DWI. KEY POINTS: Question How should diffusion-weighted images be combined with T2-weighted images in predicting complete tumor response of rectal cancer on MRI following CRT? Findings Compared to mrTRG, the AND criterion yielded higher specificity without a significant difference in sensitivity, while the OR and modMR-TRG criteria yielded higher sensitivity but lower specificity. Clinical relevance Our study explores practical strategies for integrating DWI with T2WI that can be applied in daily practice. The AND criterion by using DWI conservatively is preferred over OR criteria, which results in a disproportionately higher number of additional false-positives than additional true-positives.
Indexed as
Identifiers
40815309What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.